Drug Repurposing: Strengthening Outcomes of Existing Pharmaceuticals to Shift Emerging Health Challenges
A special issue of Pharmacy (ISSN 2226-4787). This special issue belongs to the section "Pharmacy Practice and Practice-Based Research".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 77
Special Issue Editors
Interests: drug regulation; pharmacovigilance; clinical pharmacy; pharnmacoepidemiology; hospital pharmacy
Special Issue Information
Dear Colleagues,
Drug repurposing is an innovative and increasingly successful approach to identify new therapeutic uses for approved or investigational drugs. This strategy is supported by the shared biological mechanisms underlying many diseases and the concept of pleiotropic drug action. Among its key advantages are a reduced risk of failure—owing to established safety and efficacy in preclinical models and humans—and a significant shortening of the overall development timeline.
Drug repurposing plays a particularly important role during public health crises, where rapid access to effective treatments is critical. Moreover, the search for new indications often leads to the discovery of novel drug targets or signaling pathways, thereby advancing our understanding of disease biology.
This Special Issue aims to highlight both the innovative and practical dimensions of drug repurposing while also exploring its intersections with drug regulation and pharmacological research. We welcome original research articles, as well as comprehensive reviews, that contribute to advancing this dynamic field.
Prof. Dr. Ilko Getov
Prof. Dr. Hristina Lebanova
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacy is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- repurposing
- repositioning
- drug utilization research
- drug regulation
- clinical trials
- pharmacoeconomics
- unmet medical needs
- marketing authorization
- drug rediscovery
- extension of indications
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
